On 4/19/2017, Shares of Brooks Automation, Inc. (NASDAQ:BRKS) closed at $22.34 in last trading day. After noting the initial trading entry at $22.08, it reached to a day’s high of $22.51 and moved to a day’s low of $21.98. The recent daily volume was 455.7 thousand as contrast to it’s an average volume of 577.04 thousand.
The last close of the Brooks Automation, Inc. stock reflects that it traded up +4.53% from its 50-day moving average of $21.37. The stock traded above +25.48% to its 200-day MA of $17.80. Furthermore, it moved lower -2.06% from its 52-week high of $22.81 and +148.50% up from $8.99, which is 52-week low of the stock.
During the last month, Brooks Automation, Inc.’s (BRKS) has changed 2.06% and performed 69.93% over the last 6 months. The mean rating score for this stock is at 2.00. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 3.09% in recent month and observed Weekly Volatility of 2.51%.
Brooks Automation, Inc. provides automation and cryogenic solutions for various applications and markets. It operates through two segments, Brooks Semiconductor Solutions Group and Brooks Life Science Systems. The Brooks Semiconductor Solutions Group segment offers critical automated transport, vacuum, and contamination controls solutions and services. This segment’s products include atmospheric and vacuum robots, robotic modules, and tool automation systems that provide precision handling and clean wafer environments; automated cleaning and inspection systems for wafer carriers, as well as reticle pod cleaners and stockers; and vacuum pumping and thermal management solutions for use in critical process vacuum applications. This segment also provides support services, including repair, diagnostic, and installation, as well as spare parts and productivity enhancement upgrades. The Brooks Life Science Systems segment provides automated cold storage systems; consumables, including various formats of racks, tubes, caps, plates and foils; and instruments used for labeling, bar coding, capping, decapping, auditing, sealing, peeling, and piercing tubes and plates. This segment also provides sample management services, such as on-site and off-site sample storage, cold chain logistics, sample relocation, bio-processing solutions, disaster recovery, and business continuity, as well as project management and consulting. In addition, this segment offers sample intelligence software solutions and customer technology integration; and laboratory work flow scheduling for life science tools and instrument work cells, sample inventory and logistics, environmental and temperature monitoring, and clinical trial and consent management, as well as planning, data management, virtualization, and visualization services. The company sells its products and services in approximately 50 countries. Brooks Automation, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Aduro Biotech, Inc. (NASDAQ:ADRO) finalized the last transaction at value of $9.30. The company maintained volume of 433.01 thousand shares. In past trading day, the stock hit the maximum price of $9.65 and touched to minimum value of $9.10. It has a market cap of $ 632.38M.
As of last trade close, the stock is trading downside -43.40% from its one year high of $16.43 and moved +28.10% upward from $7.26, which is one year low of the stock.
The stock traded below -10.37% from its 50-day moving average of $10.38. Furthermore, the stock moved -19.07% to its 200-day MA of $ 11.49.
ADURO BIOTECH, INC.’s (ADRO) moved with shift of 0.00% in the past week. Over the last three months, the shares of the company have changed -18.42% and performed -18.71% over the last six months. The stock currently has Monthly Volatility of 6.32% and Weekly Volatility of 5.46%.
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the company’s products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has a collaboration agreement with Janssen Biotech, Inc. to develop drugs for the treatment of prostate and lung cancers; and development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.